Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior or how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Clinical trial starts slowed to below pre-pandemic levels last year, IQVIA analysis finds

Biopharma R&D spending rebounded in 2023, up $11 billion from 2022 following a steep post-pandemic decline. But the number of new clinical trial starts slowed

February 23, 2024

Helene and CVS land double whammy for 25,000 patients who survive on IV nutrition

The CVS representative popped into Lisa Trumble’s third-floor Berkshire Medical Center hospital room in Pittsfield, Massachusetts, to announce that everything was arranged for Trumble to

October 18, 2024

Immune imprinting: The crux of waning COVID-19 booster effectiveness against new variants

The study in Nature Microbiology reviews the concept of immune imprinting and its influence on antibody responses to SARS-CoV-2, highlighting challenges for COVID-19 booster vaccination

November 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.